UBS Group
ERAS icon

UBS Group’s Erasca ERAS Stock Holding History

UBS Group’s Portfolio ERAS Stock Details ERAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.9M Buy
1,848,580
+1,678,049
+984% +$19.8M ﹤0.01% 2178
2025
Q4 		$634K Buy
170,531
+24,370
+17% +$68.5K ﹤0.01% 5936
2025
Q3 		$319K Sell
146,161
-349,486
-71% -$556K ﹤0.01% 6396
2025
Q2 		$629K Buy
495,647
+357,214
+258% +$478K ﹤0.01% 5828
2025
Q1 		$190K Sell
138,433
-54,735
-28% -$93.9K ﹤0.01% 6594
2024
Q4 		$485K Sell
193,168
-37,454
-16% -$103K ﹤0.01% 5868
2024
Q3 		$630K Buy
230,622
+185,496
+411% +$523K ﹤0.01% 5047
2024
Q2 		$106K Sell
45,126
-34,395
-43% -$74.2K ﹤0.01% 6126
2024
Q1 		$164K Sell
79,521
-32,324
-29% -$64.6K ﹤0.01% 5977
2023
Q4 		$238K Buy
111,845
+57,153
+104% +$121K ﹤0.01% 5661
2023
Q3 		$108K Sell
54,692
-126
-0.2% -$323 ﹤0.01% 5787
2023
Q2 		$151K Buy
54,818
+23,553
+75% +$67.1K ﹤0.01% 5678
2023
Q1 		$94.1K Sell
31,265
-166,054
-84% -$604K ﹤0.01% 5951
2022
Q4 		$850K Buy
197,319
+194,444
+6,763% +$1.32M ﹤0.01% 4230
2022
Q3 		$23K Buy
+2,875
New +$23.2K ﹤0.01% 7193
2022
Q1 		– Sell
-7,529
Closed -$118K – 10412
2021
Q4 		$118K Buy
7,529
+6,804
+938% +$116K ﹤0.01% 6146
2021
Q3 		$15K Buy
+725
New +$15K ﹤0.01% 7497

Other funds holding ERAS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

UBS Group's ERAS Position: Q1 2026 in Review

UBS Group increased its Erasca (ERAS) stake by 984% in Q1 2026, buying an estimated $19.8M and bringing the position to 1,848,580 shares worth $29.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2178.

UBS Group first reported a position in ERAS in Q3 2021 and has held it in 17 quarters since. 225 funds tracked by Wall St. Rank hold ERAS as of Q1 2026.

  • UBS Group held 1,848,580 shares of Erasca worth $29.9M as of Q1 2026.
  • UBS Group bought 1,678,049 Erasca shares in Q1 2026, an estimated $19.8M.
  • Erasca made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2178 holding.
  • UBS Group first reported a position in Erasca in Q3 2021 and has held it in 17 quarters since.
  • 225 funds tracked by Wall St. Rank held Erasca as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.